Can the expression of the metalloproteinase 9 gene and its inhibitor be considered as markers of heart failure?

Background: Heart failure (HF) is a major cause of mortality in developed countries. Its formation is associated with a change in the transcriptional activity of many genes. The aim of the study was to select, from the group of genes related to coronary atherosclerosis and heart failure, genes differentiating patients with coronary heart disease and heart failure on the basis of myocardial ischemia from healthy people, and then genes differentiating patients with various stages of heart failure.

Methods: The study was carried out using the oligonucleotide microarray technique HG-U133A (Affymetrix, Santa Clara, CA, USA). Cluster analysis showed a homogeneous division of the study group into patients with heart failure and healthy patients with excluded coronary artery disease and patients with heart failure depending on the size of the left ventricle ejection fraction.

Results: The study showed that genes differentiating the group of patients from healthy people were: TGF-β1, TIMP-1 and MMP-9. The analysis also showed that genes differentiated patients with advanced heart failure in the course of coronary disease and left ventricular ejection fraction (LVEF) 20% and patients from the group with 40% LVEF were MMP-9 and TIMP-1.

Conclusions: Extracting from the group of genes related to coronary atherosclerosis and cardiac failure: MMP-9, TGF-β1 and TIMP-1 differentiating patients with heart failure on the basis of myocardial ischemia in varying degrees of severity from healthy people may indicate their significant contribution to disease development. Also increased expression of the metalloproteinase gene 9 (MMP-9) with a simultaneous decrease in the expression of its tissue inhibitor 1 (TIMP-1) in the studied group of patients with ischemic heart failure differing in left ventricular ejection fraction LVEF makes them the markers of progression in failure.